JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $42
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) but lowers the price target from $43 to $42.
August 09, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Crinetics Pharmaceuticals but lowers the price target from $43 to $42.
The news is directly related to Crinetics Pharmaceuticals. While the maintenance of the Market Outperform rating is positive, the lowering of the price target might have a neutral to slightly negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100